SCHEDULE: Janus Henderson Boosts IDEAYA BIOSCIENCES Stake to 6.9%

Janus Henderson Group plc has disclosed an increased beneficial ownership of 6.9% in IDEAYA BIOSCIENCES, INC., holding 6,206,238 common shares.

Summary

• Janus Henderson Group plc, a Jersey-based entity, has filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in IDEAYA BIOSCIENCES, INC.
• Janus Henderson Group plc beneficially owns 6,206,238 shares of IDEAYA BIOSCIENCES, INC. Common Stock.
• This holding represents 6.9% of the total class of securities.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 6,206,238 shares.
• The event requiring this filing occurred on June 30, 2025.
• The reporting person is classified as an Investment Adviser (IA) and a Parent Holding Company (HC).
• Indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML are registered investment advisers providing investment advice to Managed Portfolios.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing beneficial ownership. It does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects, beyond the fact that a large institution holds a significant stake.

Positives

• A significant institutional investor, Janus Henderson Group plc, maintains a substantial stake in IDEAYA BIOSCIENCES, INC., indicating continued confidence or strategic interest.
• The holding is for investment purposes in the ordinary course of business, not for control, suggesting a passive investment strategy.

Negatives

• No specific negative information is disclosed in this beneficial ownership report.

Risks

• No specific risks related to IDEAYA BIOSCIENCES, INC. are detailed in this beneficial ownership filing. The filing itself is a disclosure of ownership, not a risk assessment.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Management Comments

• This filing does not contain direct quotes or paraphrased statements from company management of IDEAYA BIOSCIENCES, INC. It includes a certification from Janus Henderson Group plc's Head of North America Compliance, Kristin Mariani, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing reflects an institutional investment in the biotechnology sector, where significant holdings by large asset managers like Janus Henderson are common. Such investments typically indicate a long-term view on the growth potential of companies developing novel therapies, aligning with broader trends of capital allocation towards innovative life sciences firms.

Comparison to Industry Standards

• This filing is a standard beneficial ownership disclosure (Schedule 13G) for an institutional investor holding more than 5% of a company's class of securities.
• The 6.9% stake held by Janus Henderson Group plc in IDEAYA BIOSCIENCES, INC. is a notable position, consistent with the size of holdings seen from major asset managers in emerging biotechnology companies.
• For instance, similar institutional stakes are often observed in companies like Moderna (MRNA) or BioNTech (BNTX) during their growth phases, where large funds take significant positions.
• The nature of the holding, being for investment purposes and not control, aligns with typical passive institutional investment strategies in the biotech space, where funds aim to benefit from scientific advancements and market growth rather than direct operational influence.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by Janus Henderson Group plc may be viewed positively by other shareholders, as it signals confidence from a major investor.
• Company Management: Awareness of a large institutional holder can influence management's focus on shareholder value and corporate governance.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for IDEAYA BIOSCIENCES, INC. or Janus Henderson Group plc beyond the ongoing reporting requirements for beneficial ownership.

Key Dates

Keywords

IDEAYA BIOSCIENCES, Janus Henderson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Healthcare Investment, Institutional Holding